Archives
-
Chloroquine BA1002: Practical Research Protocol
2026-08-14
This guide explains how to prepare, apply, and quality-check Chloroquine (BA1002) in lysosomal, autophagy, cancer, antiviral, malaria, and immune-modulation workflows. It is intended for controlled laboratory research, not for converting dossier or clinical information into patient dosing or assuming efficacy in an unvalidated model.
-
(-)-Blebbistatin for Cardiac MEA Workflows
2026-08-14
Use (-)-Blebbistatin as a reversible non-muscle myosin II perturbation alongside transparent microelectrode arrays to separate electrical, metabolic, and mechanical effects in cardiac models. This workflow translates a high-density multimodal platform into practical assay controls, dose-finding steps, and troubleshooting guidance.
-
G-15: G Protein-Coupled Estrogen Receptor Antagonist
2026-08-13
G-15 is a selective G protein-coupled estrogen receptor antagonist for separating GPR30/GPER signaling from classical ERα and ERβ activity. This workflow-centered guide shows how to use it in calcium, PI3K/Akt, proliferation, and mechanistic receptor studies, with practical controls for interpreting environmental and neurobiological models.
-
VX-702 Workflows for p38α MAPK Research
2026-08-13
VX-702 combines potent, selective p38α MAPK inhibition with a practical framework for studying cytokine release, platelet preservation, arthritis biology, and cardiac stress responses. This guide translates its ATP-competitive profile and emerging dephosphorylation mechanism into reproducible assay workflows, controls, and troubleshooting decisions.
-
Inonotus hispidus Polypeptide in Periodontitis
2026-08-12
The reference study presents an Inonotus hispidus polypeptide preparation that acts across bacterial, inflammatory, bone, microbiome, and clinical dimensions of periodontitis. Its findings connect antimicrobial activity against Porphyromonas gingivalis with reduced inflammatory bone loss and implicate β-catenin/NF-κB signaling as a mechanistic pathway, while also identifying important limitations for translation.
-
GTP Solution for p21 mRNA Workflows
2026-08-12
GTP Solution (100 mM) supports controlled in vitro transcription workflows for research programs developing p21 mRNA–loaded lipid nanoparticles. This article connects nucleotide handling, RNA quality control, and localized bladder cancer assay design while separating evidence from practical optimization recommendations.
-
Pyridostigmine and α7 nAChR in Placental PE
2026-08-11
The reference study identifies placental necroptosis as a pharmacologically tractable component of preeclampsia-like pathology in RUPP rats. By showing that α-bungarotoxin eliminates pyridostigmine-associated benefits, the work connects enhanced non-neuronal cholinergic signaling to α7 nAChR-dependent control of placental inflammation, oxidative stress, and trophoblast dysfunction.
-
Acetylspiramycin: From MICs to Translation
2026-08-11
Acetylspiramycin, or Spiramycin B, offers translational researchers a useful bridge between ribosomal mechanism, antimicrobial resistance surveillance, and host-response studies. This article interprets recent Mycoplasma pneumoniae data, outlines a disciplined validation workflow, and explains how to use the compound as a research tool without overstating in vitro findings.
-
N3-kethoxal: Reading Nucleic Acid Accessibility
2026-08-10
N3-kethoxal is a membrane-permeable guanine probe that converts transient RNA and single-stranded DNA exposure into a clickable covalent signal. This article explains how to interpret that signal in structure mapping, genomic accessibility studies, and R-loop-focused assay design.
-
Amphotericin B Biofilm Research Workflow
2026-08-09
Build more informative Candida albicans biofilm assays by pairing Amphotericin B membrane injury with PP2A–autophagy measurements. This workflow also shows how to separate direct fungal killing from immune signaling, formulation artifacts, and pathway-driven drug resistance.
-
Jasplakinolide: From Actin to Assay Design
2026-08-08
Jasplakinolide is an actin polymerization inducer that can reveal how filament stabilization reshapes cellular phenotypes. This guide combines molecular mechanism, assay architecture, and chemical-genetic reasoning to improve interpretation of cytoskeletal experiments.
-
Amphotericin B: From Pores to Assay Design
2026-08-07
Amphotericin B is a benchmark polyene antifungal antibiotic whose membrane activity can be studied more rigorously by separating sterol-dependent damage from downstream immune signaling. This article translates classic protoplast-lysis logic into a modern framework for fungal infection research and reproducible assay interpretation.
-
Bacitracin (B1670): Technical Guide for Antibacterial Resear
2026-08-07
Bacitracin (B1670) is a peptide antibiotic designed for laboratory workflows investigating bacterial cell wall and peptidoglycan synthesis disruption in both gram-positive and gram-negative bacteria. It should be used exclusively for scientific research and is not appropriate for diagnostic or medical applications. Proper protocol adherence ensures reproducibility and effective antibacterial research outcomes.
-
Bacitracin (B1670): Technical Guidance for Antibacterial Res
2026-08-06
Bacitracin (B1670) is a research-grade peptide antibiotic optimized for laboratory workflows that require controlled inhibition of bacterial cell wall and peptidoglycan synthesis. Its use is appropriate for antibacterial research on gram-positive and gram-negative bacteria, but it is not suitable for diagnostic or clinical applications. Proper handling and protocol adherence are essential to ensure reproducible and reliable results.
-
Flumequine: Precision Tools for Next-Gen DNA Replication Res
2026-08-06
This article provides a thought-leadership perspective for translational researchers on leveraging Flumequine—a selective DNA topoisomerase II inhibitor—in dissecting DNA replication, cell death, and drug response mechanisms in cancer models. Blending mechanistic insight, experimental strategy, and practical guidance, it connects recent literature with strategic considerations for maximizing impact and data fidelity in in vitro studies. The discussion moves beyond standard product summaries, offering a sophisticated analysis of Flumequine’s role in addressing persistent challenges in preclinical oncology research.